Eli Lilly's retatrutide has shown significant weight loss results in a phase 3 obesity trial, with reports indicating average weight loss of up to 30.3% or 28.3% in the trial. The trial, known as TRIUMPH-1, has reportedly met its goals, with retatrutide substantially lowering weight and bmi in patients with obesity or overweight. The results suggest retatrutide may deliver powerful weight loss, with some outlets noting it achieves bariatric-level weight loss.